Continuous

influenza virus production for cell-based flu vaccines

ABOUT US

ContiVir is a research project of the Max Planck Institute in Germany. We have succesfully produced cell-based influenza virus with stable titers in continuous mode. We have also developed a highly efficient purification platform with  influenza virus recoveries beyond 98% 

OUR 

TECHNOLOGIES

We have developed a virus production system based on a continuous tubular bioreactor & a capture chromatography step with virtually full recovery for a wide range of influenza viruses.

These technologies together can be up to ten-fold more efficient than current batch production platforms.

TUBULAR BIOREACTOR
CAPTURE CHROMATOGRAPHY
 

Video of ContiVir technology:

ADVANTAGES

COMPARED TO INFLUENZA BATCH VIRUS PRODUCTION

Reduced footprint

(20 times smaller equipments)

Faster production

(save weeks or months)

Higher productivity

(reduced manufacturing costs)

GENE THERAPY
VIRAL VACCINES

Applications

Our team

Felipe Tapia, M.Sc.

Co-founder

Upstream processing specialist

  • Grey LinkedIn Icon

Pavel Marichal, M.Sc.

Co-founder

Downstream processing specialist

  • Grey LinkedIn Icon
Contact us

Sandtorstrasse 1

39106 Magdeburg

Germany

 

info@contivir.com

Related news:

- The New York Times, 2017: "Gene Therapy Hits a Peculiar Roadblock: A Virus Shortage" (click here)

- American Pharmaceutical Review, 2016: "Achieving Large-Scale Cell and Gene Therapy Manufacturing" (click here).

-U.S Food and Drug Administration, 2017: "Modernizing the Way Drugs Are Made: A Transition to Continuous Manufacturing" (click here)

- FiercePharma, 2016: "FDA urges companies to get on board with continuous manufacturing" (click here)